Blake Sprayberry

Blake Sprayberry is the Head of Commercial at Spark Therapeutics, where he is responsible for US commercial operations, commercial development, government affairs, and cross-functional activities related to the commercialization of gene therapies. He brings over 20 years of pharmaceutical and biotech industry experience, including strategy, commercial, and manufacturing.

Blake joined Spark in 2019 as Head of Commercial Development. During his tenure, Blake built the strong team, capabilities, and commercial processes needed to support and advance their gene therapy portfolio. He also led the LUXTURNA partnership with Novartis and the Spark/Roche collaboration effort, which leverages their integrated capabilities in the US and follows the Roche affiliate model outside of the US.

Prior to Spark, Blake served as the Oncology Strategy Lead for Pfizer where he was responsible for leading strategic planning and global projects. Earlier, he held commercial leadership roles at Wyeth and Pfizer, including three new product launches, expansion of the Hemophilia and Regenerative Medicine development portfolios, and leading the rhBMP-2 alliance with Medtronic. Additionally, Blake played a key role in the development of Wyeth’s biotech platform and strategy, and held roles in manufacturing, network strategy, and investment planning for in-line and portfolio biologics.

Blake served as a United States Marine Corps Officer in a variety of leadership and operations roles. He holds a BS in engineering from the US Naval Academy and an MBA from Cornell’s Johnson School of Management.